SlideShare a Scribd company logo
AstellasPharmabv.Foreducationaluseonly.
Nicardipine characteristics of
reversal & prevention of
perioperative arterial graft vasospasms
(clinical & pharmacological data integration)
January 2014
*Rydene I.V. is not registered for reversal or prevention of perioperative arterial graft vasospasms.
Consult SPC before using Rydene I.V..
AstellasPharmabv.Foreducationaluseonly.
Introduction
• Vasospasm is an important concern in coronary artery bypass grafting
• Leads to premature constriction of graft conduits
– perioperatively
– postoperatively
• Multiple mechanisms of vasospasms have been elucidated
– surgical manipulation
– biochemical factors
• Some arterial conduits are more susceptible to intense vasospasm
• Recent antispasm protocol have been developed to improve outcomes
Chanda et al. Ann Thorac Surg 2001;72:476-80. He GW. Ann Cardiothorac Surg 2013;2(4):507-518.
AstellasPharmabv.Foreducationaluseonly.
Versatility of arterial graft’s biological characteristics
Internal mammary artery:
• somatic
• higher levels of elastic laminae
• α1-adrenoceptor-dominant
• more endothelium-dependent relaxation
– release more NO
– greater EDHF-mediated hyperpolarisation1
• less atherosclerosis
Radial artery: Gastroepiploic artery:
• limb splanchnic
• more smooth muscle / less elastic more smooth muscle / less elastic
• α1- and α2-function higher pharmacological reactivity
• higher pharmacological reactivity prone to spasm
to vasoconstrictors
He GW. Arterial grafts: clinical classification and pharmacological management. Ann Cardiothorac Surg 2013;2(4):507-518.
1. EDHF: endothelium-derived hyperpolarizing factor
AstellasPharmabv.Foreducationaluseonly.
Versatility of spasmogenic stimuli
True cause of vasospasm remains unclear
• Presumed to be the extreme form of vasoconstriction responses to
spasmogenic stimuli (spasmogens)
Possible stimuli:
• Physical:
– mechanical stimulation
– temperature changes
• Pharmacological:
– nerve stimulation
– vasoconstrictors
• Type I
• Type II
He GW. Arterial grafts: clinical classification and pharmacological management. Ann Cardiothorac Surg 2013;2(4):507-518.
AstellasPharmabv.Foreducationaluseonly.
Pharmacological spasmogenic stimuli
Spasmogens:
• Type I: (most potent; endothelium-independent)
– endothelin
– prostanoids: TxA2 and PGF2α
– α1-adrenoreceptor agonists
• Type II: (weak when the endothelium is intact)
– 5-HT
He GW. Arterial grafts: clinical classification and pharmacological management. Ann Cardiothorac Surg 2013;2(4):507-518.
AstellasPharmabv.Foreducationaluseonly.
Versatility of vasospasm mechanisms
Possible mechanisms:
• Voltage-dependent:
– voltage-operated channels
• Receptor-dependent:
– receptor-operated channels
No single vasodilator is expected to be effective
to reverse or prevent all mechanisms.
He GW. Arterial grafts: clinical classification and pharmacological management. Ann Cardiothorac Surg 2013;2(4):507-518.
AstellasPharmabv.Foreducationaluseonly.
GW HE Protocol for arterial grafting (modified UHK protocol)
Antispasm solution for storage of graft after dissection:
• Nicardipine: 5 mg [30 µMol/L; -4.5 logM]
• Nitroglycerine: 5 mg [60 µMol/L; -4.3 logM]
• Multiple Electrolytes Injection: 300 ml [PLASMA-LYTE Baxter ]
Antispasm protocol once the harvesting has initiated:
• Intraoperative and postoperative low dose of Rydene I.V.*:
– nicardipine 0.5 mg/h I.V. systematically
• Ambulatory: 6-12 months of Rydene PO:
– Rydene Retard 35 mg bid
He GW. Arterial grafts: clinical classification and pharmacological management. Ann Cardiothorac Surg 2013;2(4):507-
518. *Rydene I.V. is not registered for reversal or prevention of perioperative arterial graft vasospasms.
AstellasPharmabv.Foreducationaluseonly.
Antispastic nicardipine and nitroglycerin cocktail solution
Free blood flow (cc/min):
• distal end of left thoracic artery (LITA) immediately after dissection
• wrapping plus injection of NG1 cocktail versus normal saline
Zheng et al. J Cardiovascular Surg 2012;53:783-8. 1. Nicardipine-Nitroglycerin cocktail solution
p=0,025 compared with Saline
AstellasPharmabv.Foreducationaluseonly.
Antispastic nicardipine and nitroglycerin cocktail solution
Ultrasound probe (cc/min):
• left thoracic artery after the grafting procedure
• NG1 cocktail versus normal saline
Zheng et al. J Cardiovascular Surg 2012;53:783-8. 1. Nicardipine-Nitroglycerin cocktail solution
p=0,028 compared with Saline
AstellasPharmabv.Foreducationaluseonly.
Potassium (K+)
Vasoconstrictor
Induces:
• depolarization of smooth muscle membrane
• opening of voltage-dependent calcium channel
• vascular contraction (ITA and saphenous vein)
Inhibited by:
• Ca2+ channel antagonists
Guo-Wei He et al. J Thorac Cardiovasc Surg 2000;119:94-100. ITA: Internal Thoracic Artery.
AstellasPharmabv.Foreducationaluseonly.
Antispastic effects of Ca2+ channel antagonists in radial artery
Potency (EC50 -logM) in relaxation of K+-precontracted RA:
• nicardipine potency is 2.2- and 3.6-fold higher than that of verapamil and
diltiazem1
Guo-Wei He et al. J Thorac Cardiovasc Surg 2000;119:94-100. 1. p=NS.
AstellasPharmabv.Foreducationaluseonly.
Preventive antispastic effects of nicardipine in radial artery
Mean concentration (-logM) -contraction (%) curves for nicardipine-
pretreated RA:
• nicardipine prevent K+-induced contraction of RA1
Guo-Wei He et al. J Thorac Cardiovasc Surg 2000;119:94-100. 1. p=0.003.
Control: maximum K+-induced
contraction
Pretreatment with systemic
concentration of nicardipine
• 20 ηM (-7.7 logM)
Pretreatment with topical
concentration of nicardipine
• 30 µM (-4.5 logM)
AstellasPharmabv.Foreducationaluseonly.
Antispastic effects of verapamil and diltiazem in radial artery
Mean concentration (-logM) -contraction (%) curves for nicardipine-pretreated RA:
• neither verapamil nor diltiazem showed any depressive effect on K+-induced
contraction of RA at systemic therapeutic range
Guo-Wei He et al. J Thorac Cardiovasc Surg 2000;119:94-100.
Control: maximum K+-induced
contraction
Pretreatment with systemic
concentration of diltiazem
• 60 ηM (-7.2 logM)
Pretreatment with topical
concentration of diltiazem
• 30 µM (-4.5 logM)
Pretreatment with systemic
concentration of verapamil
• 20 ηM (-7.7 logM)
AstellasPharmabv.Foreducationaluseonly.
Endothelin: cardiovascular function
Endothelium-derived vasoconstrictors
Important role in the aetiology of:
• hypertension
• cerebral vasospasm
• coronary vasospasm
• myocardial ischaemia
• renal artery stenosis
• atherosclerosis
Stimulation of endothelin receptors:
• increases the inward Ca2+ current
• raises cytosolic Ca2+
Amenta et al. J. Auton. Pharmacol. 1994;14:129-136
AstellasPharmabv.Foreducationaluseonly.
Interactions between endothelin and nicardipine in artery1
Influence of increasing concentration of endothelin on nicardipine binding:
• 10 ηM endothelin-1 reduced nicardipine binding by about 85%
Amenta et al. J. Auton. Pharmacol. 1994;14:129-136. 1. Human renal artery.
endothelin-1
endothelin-3
AstellasPharmabv.Foreducationaluseonly.
Thromboxane A2: cardiovascular function
Vasoconstrictor
Important role in the perioperative stress:
• vascular injury
• platelet activation
• vasoconstriction
• systemic hypertension = “presenting symptom”
Potentially related to:
• vasospasm-related myocardial ischemia after surgery
Tanaka et al. British Journal of Anaesthesia 2004;93(2):257–62.
AstellasPharmabv.Foreducationaluseonly.
TxA2 agonist-induced vasoconstriction in human IMA1
Concentration-response curves in human IMA contracted with TxA2:
• Maximum relaxation with nicardipine: 74%
Tanaka et al. British Journal of Anaesthesia 2004;93(2):257–62. 1. IMA: internal mammary artery
Concentration of nicardipine in topical use: -4.5 logM.
AstellasPharmabv.Foreducationaluseonly.
TxA2 agonist-induced vasoconstriction in human IMA1
Concentration-response curves in human IMA precontracted with TxA2:
• Labetalol: lack of response at the therapeutic concentration
Tanaka et al. British Journal of Anaesthesia 2004;93(2):257–62. 1. IMA: internal mammary artery
Precontraction with TxA2:
• maximum relaxation with
labetalol at the highest C°: 27%
Precontraction with
Norepinephrine:
• maximum relaxation with
labetalol: 88%
AstellasPharmabv.Foreducationaluseonly.
Effect of Nic + NTG on a mixture of vasoconstrictors
Human arterial and venous conduits1 precontracted
with a mixture of 10 times the maximum plasma concentrations of:
• endothelin-1: endothelium-derived
• + norepinephrine: sympathomimetic
• + angiotensine II: renin-angiotensin system-related
• + 5-HT: platelet derived
Average therapeutic plasma concentration of vasodilators:
• Nicardipine (56 ηMol/L; -7.3 logM) + Nitroglycerine (10 ηMol/L; -7.7 logM)
• Nitroglycerine (20 ηMol/L; -8 logM)
Chanda et al. Ann Thorac Surg 2001;72:476-80. 1. RA: radial artery, ITA: internal thoracic artery, SV: saphenous vein.
AstellasPharmabv.Foreducationaluseonly.
Precontraction effect of a mixture of vasoconstrictors1
precontraction (g) of human arteries and veins2:
• radial artery is vulnerable to the most intense vasospasm
Chanda et al. Ann Thorac Surg 2001;72:476-80. 2. RA: radial artery; ITA: internal thoracic artery; SV: saphenous vein.
1. Mixture of 10x the
maximum human plasma
concentration of:
• endothelin-1
• norepinephrine
• angiotensine II
• 5-HT
AstellasPharmabv.Foreducationaluseonly.
Vasodilative effects of NTG alone or with Nicardipine
% vasodilation in precontracted human artery and veins:
• nicardipine + nitroglycerin achieved >90% vasodilation in RA
Chanda et al. Ann Thorac Surg 2001;72:476-80. RA: radial artery, ITA: internal thoracic artery, SV: saphenous vein.
Comparison between segments: RA>ITA>SV; p<0.0001.
Precontraction with a
mixture of 10x the
maximum human plasma
concentration of:
• endothelin-1
• norepinephrine
• angiotensine II
• 5-HT
AstellasPharmabv.Foreducationaluseonly.
Nicardipine-NTG cocktail1: a new antispastic solution (NG)
new antispastic protocol:
• rapid onset, almost full relaxation
• prophylactic effects
• against different vasospasms mechanisms2
• in various arteries3
• respect of endothelial function
Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L).
2. NE: norepinephrine; K+: potassium chloride; U46619: TxA2 agonist. 3. Radial artery, Internal thoracic artery.
AstellasPharmabv.Foreducationaluseonly.
Relaxation effects of Nicardipine-NTG cocktail1 (NG)
% relaxation induced by NG cocktail in precontracted human artery:
• almost full relaxation against 3 vasoconstrictors (>90%)
Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L).
IMA (ITA): internal thoracic artery; RA: radial artery; NE: norepinephrine; K+: potassium chloride; U46619: TxA2 agonist.
AstellasPharmabv.Foreducationaluseonly.
Onset and time course of relaxation by NG cocktail1 (NG)
Relaxation induced by NG cocktail in precontracted human artery:
• relaxation reached almost the maximal in the first 20 minutes
Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L).
A: Internal thoracic artery; B: Radial artery; NE: norepinephrine; K+: potassium chloride; U46619: TxA2 agonist.
AstellasPharmabv.Foreducationaluseonly.
Prophylactic action of NG cocktail1 on induced contraction (1)
Mean concentration-contraction curves for TxA2 agonist:
• contraction was depressed to 76.4% and 69.2% of the maximal contraction
force in ITA and RA
Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L).
A: Internal thoracic artery; B: Radial artery; U46619: TxA2 agonist. Comparison vs control: ** p<.01 *** p<.001
AstellasPharmabv.Foreducationaluseonly.
Prophylactic action of NG cocktail1 on induced contraction (2)
Mean concentration-contraction curves for K+:
• contraction was depressed to 52.5% and 40.3% of the maximal contraction
force in ITA and RA
Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L).
A: Internal thoracic artery; B: Radial artery; K+: potassium chloride. Comparison vs control: ** p<.01 *** p<.001
AstellasPharmabv.Foreducationaluseonly.
Prophylactic action of NG cocktail1 on induced contraction (3)
Mean concentration-contraction curves for NE:
• contraction was depressed to 32.5% and 15.6% of the maximal contraction
force in ITA and RA
Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L).
A: Internal thoracic artery; B: Radial artery; NE: norepinephrine. Comparison vs control: ** p<.01 *** p<.001
AstellasPharmabv.Foreducationaluseonly.
Preservation of endothelial function by NG cocktail1
Mean concentration-relaxation curves for Ach in precontracted arteries:
• unchanged Ach-induced relaxation
• preserved endothelial function
Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L).
A: Internal thoracic artery; B: Radial artery; ACh: acetylcholine.
AstellasPharmabv.Foreducationaluseonly.
General conclusion
• Vasospasm remains an important concern in coronary artery bypass
grafting
• Perioperative and postoperative premature constriction of graft conduits
may be reversed or prevented by antispasm protocols.
• No single vasodilator is expected to be effective to reverse or prevent all
mechanisms.
• Arterial conduits that are more vulnerable to the most intense vasospasm
are also the most efficaciously treated.
• Nicardipine + nitroglycerin cocktail achieved rapid onset effective
relaxation and prophylactic antispastic effect at therapeutic concentration
Chanda et al. Ann Thorac Surg 2001;72:476-80. He GW. Ann Cardiothorac Surg 2013;2(4):507-518.
AstellasPharmabv.Foreducationaluseonly.
AstellasPharmabv.Foreducationaluseonly.
AstellasPharmabv.Foreducationaluseonly.
AstellasPharmabv.Foreducationaluseonly.

More Related Content

What's hot

New Oral Anticoagulants
New Oral AnticoagulantsNew Oral Anticoagulants
New Oral Anticoagulants
SCGH ED CME
 
Angiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + ValsartanAngiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + Valsartan
Jai Parekh
 
Angiongensin receptor(full permission)
Angiongensin receptor(full permission)Angiongensin receptor(full permission)
Angiongensin receptor(full permission)
drucsamal
 
Antidote for NOACs
Antidote for NOACsAntidote for NOACs
Antidote for NOACs
Vishal Vanani
 
Take home message
Take home messageTake home message
Take home message
drucsamal
 
Emergency Management of Patients Taking Direct Oral Anticoagulants
Emergency Management of Patients Taking Direct Oral AnticoagulantsEmergency Management of Patients Taking Direct Oral Anticoagulants
Emergency Management of Patients Taking Direct Oral Anticoagulants
UFJaxEMS
 
Angiotensin receptor-neprilysin inhibition(ARNI):The New Fronteir ?
Angiotensin receptor-neprilysin inhibition(ARNI):The New Fronteir ?Angiotensin receptor-neprilysin inhibition(ARNI):The New Fronteir ?
Angiotensin receptor-neprilysin inhibition(ARNI):The New Fronteir ?
drucsamal
 
Paradigm hf journal club presentation
Paradigm hf journal club presentationParadigm hf journal club presentation
Paradigm hf journal club presentation
GOPAL GHOSH
 
new oral anticoagulants versus warfarin-appraisal
new oral anticoagulants versus warfarin-appraisalnew oral anticoagulants versus warfarin-appraisal
new oral anticoagulants versus warfarin-appraisalv3venu
 
Pioneer hf
Pioneer   hfPioneer   hf
Pioneer hf
Himanshu Rana
 
Diosyn (sacubitril/valsartan)
Diosyn (sacubitril/valsartan)Diosyn (sacubitril/valsartan)
Diosyn (sacubitril/valsartan)
Sandeepkumar Balabbigari, PharmD, RPh
 
K. thanavaro the indications and uses of the novel anticoagulants
K. thanavaro the indications and uses of the novel anticoagulantsK. thanavaro the indications and uses of the novel anticoagulants
K. thanavaro the indications and uses of the novel anticoagulants
Alysia Smith
 
PARADIGM HF TRIAL
PARADIGM HF TRIALPARADIGM HF TRIAL
PARADIGM HF TRIAL
Praveen Nagula
 
Top 3 Hits en Insuficiencia cardiaca en 2014
Top 3 Hits en Insuficiencia cardiaca en 2014Top 3 Hits en Insuficiencia cardiaca en 2014
Top 3 Hits en Insuficiencia cardiaca en 2014
Sociedad Española de Cardiología
 
Oral anticoagulation in AF
Oral anticoagulation in AFOral anticoagulation in AF
Oral anticoagulation in AF
Pavan Rasalkar
 
New New Oral Anticoagulants 2014
New New Oral Anticoagulants 2014New New Oral Anticoagulants 2014
New New Oral Anticoagulants 2014
BBrauer25
 
Transition study and Pioneer HF study
Transition study and Pioneer HF studyTransition study and Pioneer HF study
Transition study and Pioneer HF study
Edgardo Kaplinsky
 
new oral anticoagulants
new oral anticoagulantsnew oral anticoagulants
new oral anticoagulantsderosaMSKCC
 
Newer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek Baliga
Newer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek BaligaNewer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek Baliga
Newer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek Baliga
Dr Vivek Baliga
 

What's hot (20)

New Oral Anticoagulants
New Oral AnticoagulantsNew Oral Anticoagulants
New Oral Anticoagulants
 
Angiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + ValsartanAngiotensin Receptor Neprilysin + Valsartan
Angiotensin Receptor Neprilysin + Valsartan
 
Angiongensin receptor(full permission)
Angiongensin receptor(full permission)Angiongensin receptor(full permission)
Angiongensin receptor(full permission)
 
Antidote for NOACs
Antidote for NOACsAntidote for NOACs
Antidote for NOACs
 
Take home message
Take home messageTake home message
Take home message
 
Emergency Management of Patients Taking Direct Oral Anticoagulants
Emergency Management of Patients Taking Direct Oral AnticoagulantsEmergency Management of Patients Taking Direct Oral Anticoagulants
Emergency Management of Patients Taking Direct Oral Anticoagulants
 
Angiotensin receptor-neprilysin inhibition(ARNI):The New Fronteir ?
Angiotensin receptor-neprilysin inhibition(ARNI):The New Fronteir ?Angiotensin receptor-neprilysin inhibition(ARNI):The New Fronteir ?
Angiotensin receptor-neprilysin inhibition(ARNI):The New Fronteir ?
 
Paradigm hf journal club presentation
Paradigm hf journal club presentationParadigm hf journal club presentation
Paradigm hf journal club presentation
 
new oral anticoagulants versus warfarin-appraisal
new oral anticoagulants versus warfarin-appraisalnew oral anticoagulants versus warfarin-appraisal
new oral anticoagulants versus warfarin-appraisal
 
Pioneer hf
Pioneer   hfPioneer   hf
Pioneer hf
 
Diosyn (sacubitril/valsartan)
Diosyn (sacubitril/valsartan)Diosyn (sacubitril/valsartan)
Diosyn (sacubitril/valsartan)
 
K. thanavaro the indications and uses of the novel anticoagulants
K. thanavaro the indications and uses of the novel anticoagulantsK. thanavaro the indications and uses of the novel anticoagulants
K. thanavaro the indications and uses of the novel anticoagulants
 
PARADIGM HF TRIAL
PARADIGM HF TRIALPARADIGM HF TRIAL
PARADIGM HF TRIAL
 
Top 3 Hits en Insuficiencia cardiaca en 2014
Top 3 Hits en Insuficiencia cardiaca en 2014Top 3 Hits en Insuficiencia cardiaca en 2014
Top 3 Hits en Insuficiencia cardiaca en 2014
 
Afib NOAC residency pres
Afib NOAC residency presAfib NOAC residency pres
Afib NOAC residency pres
 
Oral anticoagulation in AF
Oral anticoagulation in AFOral anticoagulation in AF
Oral anticoagulation in AF
 
New New Oral Anticoagulants 2014
New New Oral Anticoagulants 2014New New Oral Anticoagulants 2014
New New Oral Anticoagulants 2014
 
Transition study and Pioneer HF study
Transition study and Pioneer HF studyTransition study and Pioneer HF study
Transition study and Pioneer HF study
 
new oral anticoagulants
new oral anticoagulantsnew oral anticoagulants
new oral anticoagulants
 
Newer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek Baliga
Newer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek BaligaNewer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek Baliga
Newer Oral Anticoagulants In Atrial Fibrillation - Dr Vivek Baliga
 

Similar to Reversal & prevention of perioperative coronary graft vasospams

ACC UPDATE 2018
ACC UPDATE 2018ACC UPDATE 2018
ACC UPDATE 2018
Praveen Nagula
 
Azelnidipine
AzelnidipineAzelnidipine
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
vaibhavyawalkar
 
Perioperative Use Of RAAS Antagonists
Perioperative Use Of RAAS AntagonistsPerioperative Use Of RAAS Antagonists
Perioperative Use Of RAAS Antagonists
MedPeds Hospitalist
 
Cardiogenic shock
Cardiogenic shockCardiogenic shock
Cardiogenic shock
Dr. Armaan Singh
 
Advances in Medical Management of Heart Failure
Advances in Medical Management of Heart FailureAdvances in Medical Management of Heart Failure
Advances in Medical Management of Heart Failure
Praveen Nagula
 
Hypertension management- Angina IHD
Hypertension management- Angina IHDHypertension management- Angina IHD
Hypertension management- Angina IHDcardiositeindia
 
Cilnidipine in Renoprotection.pptx
Cilnidipine in Renoprotection.pptxCilnidipine in Renoprotection.pptx
Cilnidipine in Renoprotection.pptx
ParikshitMishra15
 
THE ENGAGE AF TIMI 48 trial
THE ENGAGE AF TIMI 48 trialTHE ENGAGE AF TIMI 48 trial
THE ENGAGE AF TIMI 48 trial
Praveen Nagula
 
Blood Pressure Control in Neuro ICU
Blood Pressure Control in Neuro ICUBlood Pressure Control in Neuro ICU
Blood Pressure Control in Neuro ICUDr.Mahmoud Abbas
 
azelnidipine.pptx
azelnidipine.pptxazelnidipine.pptx
azelnidipine.pptx
SharatVijapur1
 
Oxidative stress and atrial fibrillation: a long journey in to the clinic? (P...
Oxidative stress and atrial fibrillation: a long journey in to the clinic? (P...Oxidative stress and atrial fibrillation: a long journey in to the clinic? (P...
Oxidative stress and atrial fibrillation: a long journey in to the clinic? (P...
Vall d'Hebron Institute of Research (VHIR)
 
Update on Hepatorenal syndrome
Update on Hepatorenal syndromeUpdate on Hepatorenal syndrome
Update on Hepatorenal syndrome
yehtet aung
 
Rational choice of inotropes and vasopressors in intensive care unit
Rational choice of inotropes and vasopressors in intensive care unitRational choice of inotropes and vasopressors in intensive care unit
Rational choice of inotropes and vasopressors in intensive care unit
Saneesh P J
 
early initiation of arni.pptx
early initiation of arni.pptxearly initiation of arni.pptx
early initiation of arni.pptx
dkapila2002
 
Potential new therapies in heart failure
Potential new therapies in heart failurePotential new therapies in heart failure
Potential new therapies in heart failure
Anirudhya J
 
Desmoteplase
DesmoteplaseDesmoteplase
Desmoteplase
Hanish Kodali
 
0319report
0319report0319report
0319report
Shen-Chih Wang
 
Biomarkers in heart failure
Biomarkers in heart failureBiomarkers in heart failure
Biomarkers in heart failure
Himanshu Rana
 

Similar to Reversal & prevention of perioperative coronary graft vasospams (20)

ACC UPDATE 2018
ACC UPDATE 2018ACC UPDATE 2018
ACC UPDATE 2018
 
Azelnidipine
AzelnidipineAzelnidipine
Azelnidipine
 
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
Summary of PROVE-HF and GUIDE-IT studies by Dr. Vaibhav Yawalkar MD, DM Cardi...
 
Perioperative Use Of RAAS Antagonists
Perioperative Use Of RAAS AntagonistsPerioperative Use Of RAAS Antagonists
Perioperative Use Of RAAS Antagonists
 
Cardiogenic shock
Cardiogenic shockCardiogenic shock
Cardiogenic shock
 
Advances in Medical Management of Heart Failure
Advances in Medical Management of Heart FailureAdvances in Medical Management of Heart Failure
Advances in Medical Management of Heart Failure
 
Hypertension management- Angina IHD
Hypertension management- Angina IHDHypertension management- Angina IHD
Hypertension management- Angina IHD
 
Cilnidipine in Renoprotection.pptx
Cilnidipine in Renoprotection.pptxCilnidipine in Renoprotection.pptx
Cilnidipine in Renoprotection.pptx
 
THE ENGAGE AF TIMI 48 trial
THE ENGAGE AF TIMI 48 trialTHE ENGAGE AF TIMI 48 trial
THE ENGAGE AF TIMI 48 trial
 
Blood Pressure Control in Neuro ICU
Blood Pressure Control in Neuro ICUBlood Pressure Control in Neuro ICU
Blood Pressure Control in Neuro ICU
 
azelnidipine.pptx
azelnidipine.pptxazelnidipine.pptx
azelnidipine.pptx
 
Oxidative stress and atrial fibrillation: a long journey in to the clinic? (P...
Oxidative stress and atrial fibrillation: a long journey in to the clinic? (P...Oxidative stress and atrial fibrillation: a long journey in to the clinic? (P...
Oxidative stress and atrial fibrillation: a long journey in to the clinic? (P...
 
Update on Hepatorenal syndrome
Update on Hepatorenal syndromeUpdate on Hepatorenal syndrome
Update on Hepatorenal syndrome
 
Rational choice of inotropes and vasopressors in intensive care unit
Rational choice of inotropes and vasopressors in intensive care unitRational choice of inotropes and vasopressors in intensive care unit
Rational choice of inotropes and vasopressors in intensive care unit
 
early initiation of arni.pptx
early initiation of arni.pptxearly initiation of arni.pptx
early initiation of arni.pptx
 
Trials of ace inhibitors
Trials of ace inhibitorsTrials of ace inhibitors
Trials of ace inhibitors
 
Potential new therapies in heart failure
Potential new therapies in heart failurePotential new therapies in heart failure
Potential new therapies in heart failure
 
Desmoteplase
DesmoteplaseDesmoteplase
Desmoteplase
 
0319report
0319report0319report
0319report
 
Biomarkers in heart failure
Biomarkers in heart failureBiomarkers in heart failure
Biomarkers in heart failure
 

Reversal & prevention of perioperative coronary graft vasospams

  • 1. AstellasPharmabv.Foreducationaluseonly. Nicardipine characteristics of reversal & prevention of perioperative arterial graft vasospasms (clinical & pharmacological data integration) January 2014 *Rydene I.V. is not registered for reversal or prevention of perioperative arterial graft vasospasms. Consult SPC before using Rydene I.V..
  • 2. AstellasPharmabv.Foreducationaluseonly. Introduction • Vasospasm is an important concern in coronary artery bypass grafting • Leads to premature constriction of graft conduits – perioperatively – postoperatively • Multiple mechanisms of vasospasms have been elucidated – surgical manipulation – biochemical factors • Some arterial conduits are more susceptible to intense vasospasm • Recent antispasm protocol have been developed to improve outcomes Chanda et al. Ann Thorac Surg 2001;72:476-80. He GW. Ann Cardiothorac Surg 2013;2(4):507-518.
  • 3. AstellasPharmabv.Foreducationaluseonly. Versatility of arterial graft’s biological characteristics Internal mammary artery: • somatic • higher levels of elastic laminae • α1-adrenoceptor-dominant • more endothelium-dependent relaxation – release more NO – greater EDHF-mediated hyperpolarisation1 • less atherosclerosis Radial artery: Gastroepiploic artery: • limb splanchnic • more smooth muscle / less elastic more smooth muscle / less elastic • α1- and α2-function higher pharmacological reactivity • higher pharmacological reactivity prone to spasm to vasoconstrictors He GW. Arterial grafts: clinical classification and pharmacological management. Ann Cardiothorac Surg 2013;2(4):507-518. 1. EDHF: endothelium-derived hyperpolarizing factor
  • 4. AstellasPharmabv.Foreducationaluseonly. Versatility of spasmogenic stimuli True cause of vasospasm remains unclear • Presumed to be the extreme form of vasoconstriction responses to spasmogenic stimuli (spasmogens) Possible stimuli: • Physical: – mechanical stimulation – temperature changes • Pharmacological: – nerve stimulation – vasoconstrictors • Type I • Type II He GW. Arterial grafts: clinical classification and pharmacological management. Ann Cardiothorac Surg 2013;2(4):507-518.
  • 5. AstellasPharmabv.Foreducationaluseonly. Pharmacological spasmogenic stimuli Spasmogens: • Type I: (most potent; endothelium-independent) – endothelin – prostanoids: TxA2 and PGF2α – α1-adrenoreceptor agonists • Type II: (weak when the endothelium is intact) – 5-HT He GW. Arterial grafts: clinical classification and pharmacological management. Ann Cardiothorac Surg 2013;2(4):507-518.
  • 6. AstellasPharmabv.Foreducationaluseonly. Versatility of vasospasm mechanisms Possible mechanisms: • Voltage-dependent: – voltage-operated channels • Receptor-dependent: – receptor-operated channels No single vasodilator is expected to be effective to reverse or prevent all mechanisms. He GW. Arterial grafts: clinical classification and pharmacological management. Ann Cardiothorac Surg 2013;2(4):507-518.
  • 7. AstellasPharmabv.Foreducationaluseonly. GW HE Protocol for arterial grafting (modified UHK protocol) Antispasm solution for storage of graft after dissection: • Nicardipine: 5 mg [30 µMol/L; -4.5 logM] • Nitroglycerine: 5 mg [60 µMol/L; -4.3 logM] • Multiple Electrolytes Injection: 300 ml [PLASMA-LYTE Baxter ] Antispasm protocol once the harvesting has initiated: • Intraoperative and postoperative low dose of Rydene I.V.*: – nicardipine 0.5 mg/h I.V. systematically • Ambulatory: 6-12 months of Rydene PO: – Rydene Retard 35 mg bid He GW. Arterial grafts: clinical classification and pharmacological management. Ann Cardiothorac Surg 2013;2(4):507- 518. *Rydene I.V. is not registered for reversal or prevention of perioperative arterial graft vasospasms.
  • 8. AstellasPharmabv.Foreducationaluseonly. Antispastic nicardipine and nitroglycerin cocktail solution Free blood flow (cc/min): • distal end of left thoracic artery (LITA) immediately after dissection • wrapping plus injection of NG1 cocktail versus normal saline Zheng et al. J Cardiovascular Surg 2012;53:783-8. 1. Nicardipine-Nitroglycerin cocktail solution p=0,025 compared with Saline
  • 9. AstellasPharmabv.Foreducationaluseonly. Antispastic nicardipine and nitroglycerin cocktail solution Ultrasound probe (cc/min): • left thoracic artery after the grafting procedure • NG1 cocktail versus normal saline Zheng et al. J Cardiovascular Surg 2012;53:783-8. 1. Nicardipine-Nitroglycerin cocktail solution p=0,028 compared with Saline
  • 10. AstellasPharmabv.Foreducationaluseonly. Potassium (K+) Vasoconstrictor Induces: • depolarization of smooth muscle membrane • opening of voltage-dependent calcium channel • vascular contraction (ITA and saphenous vein) Inhibited by: • Ca2+ channel antagonists Guo-Wei He et al. J Thorac Cardiovasc Surg 2000;119:94-100. ITA: Internal Thoracic Artery.
  • 11. AstellasPharmabv.Foreducationaluseonly. Antispastic effects of Ca2+ channel antagonists in radial artery Potency (EC50 -logM) in relaxation of K+-precontracted RA: • nicardipine potency is 2.2- and 3.6-fold higher than that of verapamil and diltiazem1 Guo-Wei He et al. J Thorac Cardiovasc Surg 2000;119:94-100. 1. p=NS.
  • 12. AstellasPharmabv.Foreducationaluseonly. Preventive antispastic effects of nicardipine in radial artery Mean concentration (-logM) -contraction (%) curves for nicardipine- pretreated RA: • nicardipine prevent K+-induced contraction of RA1 Guo-Wei He et al. J Thorac Cardiovasc Surg 2000;119:94-100. 1. p=0.003. Control: maximum K+-induced contraction Pretreatment with systemic concentration of nicardipine • 20 ηM (-7.7 logM) Pretreatment with topical concentration of nicardipine • 30 µM (-4.5 logM)
  • 13. AstellasPharmabv.Foreducationaluseonly. Antispastic effects of verapamil and diltiazem in radial artery Mean concentration (-logM) -contraction (%) curves for nicardipine-pretreated RA: • neither verapamil nor diltiazem showed any depressive effect on K+-induced contraction of RA at systemic therapeutic range Guo-Wei He et al. J Thorac Cardiovasc Surg 2000;119:94-100. Control: maximum K+-induced contraction Pretreatment with systemic concentration of diltiazem • 60 ηM (-7.2 logM) Pretreatment with topical concentration of diltiazem • 30 µM (-4.5 logM) Pretreatment with systemic concentration of verapamil • 20 ηM (-7.7 logM)
  • 14. AstellasPharmabv.Foreducationaluseonly. Endothelin: cardiovascular function Endothelium-derived vasoconstrictors Important role in the aetiology of: • hypertension • cerebral vasospasm • coronary vasospasm • myocardial ischaemia • renal artery stenosis • atherosclerosis Stimulation of endothelin receptors: • increases the inward Ca2+ current • raises cytosolic Ca2+ Amenta et al. J. Auton. Pharmacol. 1994;14:129-136
  • 15. AstellasPharmabv.Foreducationaluseonly. Interactions between endothelin and nicardipine in artery1 Influence of increasing concentration of endothelin on nicardipine binding: • 10 ηM endothelin-1 reduced nicardipine binding by about 85% Amenta et al. J. Auton. Pharmacol. 1994;14:129-136. 1. Human renal artery. endothelin-1 endothelin-3
  • 16. AstellasPharmabv.Foreducationaluseonly. Thromboxane A2: cardiovascular function Vasoconstrictor Important role in the perioperative stress: • vascular injury • platelet activation • vasoconstriction • systemic hypertension = “presenting symptom” Potentially related to: • vasospasm-related myocardial ischemia after surgery Tanaka et al. British Journal of Anaesthesia 2004;93(2):257–62.
  • 17. AstellasPharmabv.Foreducationaluseonly. TxA2 agonist-induced vasoconstriction in human IMA1 Concentration-response curves in human IMA contracted with TxA2: • Maximum relaxation with nicardipine: 74% Tanaka et al. British Journal of Anaesthesia 2004;93(2):257–62. 1. IMA: internal mammary artery Concentration of nicardipine in topical use: -4.5 logM.
  • 18. AstellasPharmabv.Foreducationaluseonly. TxA2 agonist-induced vasoconstriction in human IMA1 Concentration-response curves in human IMA precontracted with TxA2: • Labetalol: lack of response at the therapeutic concentration Tanaka et al. British Journal of Anaesthesia 2004;93(2):257–62. 1. IMA: internal mammary artery Precontraction with TxA2: • maximum relaxation with labetalol at the highest C°: 27% Precontraction with Norepinephrine: • maximum relaxation with labetalol: 88%
  • 19. AstellasPharmabv.Foreducationaluseonly. Effect of Nic + NTG on a mixture of vasoconstrictors Human arterial and venous conduits1 precontracted with a mixture of 10 times the maximum plasma concentrations of: • endothelin-1: endothelium-derived • + norepinephrine: sympathomimetic • + angiotensine II: renin-angiotensin system-related • + 5-HT: platelet derived Average therapeutic plasma concentration of vasodilators: • Nicardipine (56 ηMol/L; -7.3 logM) + Nitroglycerine (10 ηMol/L; -7.7 logM) • Nitroglycerine (20 ηMol/L; -8 logM) Chanda et al. Ann Thorac Surg 2001;72:476-80. 1. RA: radial artery, ITA: internal thoracic artery, SV: saphenous vein.
  • 20. AstellasPharmabv.Foreducationaluseonly. Precontraction effect of a mixture of vasoconstrictors1 precontraction (g) of human arteries and veins2: • radial artery is vulnerable to the most intense vasospasm Chanda et al. Ann Thorac Surg 2001;72:476-80. 2. RA: radial artery; ITA: internal thoracic artery; SV: saphenous vein. 1. Mixture of 10x the maximum human plasma concentration of: • endothelin-1 • norepinephrine • angiotensine II • 5-HT
  • 21. AstellasPharmabv.Foreducationaluseonly. Vasodilative effects of NTG alone or with Nicardipine % vasodilation in precontracted human artery and veins: • nicardipine + nitroglycerin achieved >90% vasodilation in RA Chanda et al. Ann Thorac Surg 2001;72:476-80. RA: radial artery, ITA: internal thoracic artery, SV: saphenous vein. Comparison between segments: RA>ITA>SV; p<0.0001. Precontraction with a mixture of 10x the maximum human plasma concentration of: • endothelin-1 • norepinephrine • angiotensine II • 5-HT
  • 22. AstellasPharmabv.Foreducationaluseonly. Nicardipine-NTG cocktail1: a new antispastic solution (NG) new antispastic protocol: • rapid onset, almost full relaxation • prophylactic effects • against different vasospasms mechanisms2 • in various arteries3 • respect of endothelial function Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L). 2. NE: norepinephrine; K+: potassium chloride; U46619: TxA2 agonist. 3. Radial artery, Internal thoracic artery.
  • 23. AstellasPharmabv.Foreducationaluseonly. Relaxation effects of Nicardipine-NTG cocktail1 (NG) % relaxation induced by NG cocktail in precontracted human artery: • almost full relaxation against 3 vasoconstrictors (>90%) Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L). IMA (ITA): internal thoracic artery; RA: radial artery; NE: norepinephrine; K+: potassium chloride; U46619: TxA2 agonist.
  • 24. AstellasPharmabv.Foreducationaluseonly. Onset and time course of relaxation by NG cocktail1 (NG) Relaxation induced by NG cocktail in precontracted human artery: • relaxation reached almost the maximal in the first 20 minutes Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L). A: Internal thoracic artery; B: Radial artery; NE: norepinephrine; K+: potassium chloride; U46619: TxA2 agonist.
  • 25. AstellasPharmabv.Foreducationaluseonly. Prophylactic action of NG cocktail1 on induced contraction (1) Mean concentration-contraction curves for TxA2 agonist: • contraction was depressed to 76.4% and 69.2% of the maximal contraction force in ITA and RA Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L). A: Internal thoracic artery; B: Radial artery; U46619: TxA2 agonist. Comparison vs control: ** p<.01 *** p<.001
  • 26. AstellasPharmabv.Foreducationaluseonly. Prophylactic action of NG cocktail1 on induced contraction (2) Mean concentration-contraction curves for K+: • contraction was depressed to 52.5% and 40.3% of the maximal contraction force in ITA and RA Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L). A: Internal thoracic artery; B: Radial artery; K+: potassium chloride. Comparison vs control: ** p<.01 *** p<.001
  • 27. AstellasPharmabv.Foreducationaluseonly. Prophylactic action of NG cocktail1 on induced contraction (3) Mean concentration-contraction curves for NE: • contraction was depressed to 32.5% and 15.6% of the maximal contraction force in ITA and RA Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L). A: Internal thoracic artery; B: Radial artery; NE: norepinephrine. Comparison vs control: ** p<.01 *** p<.001
  • 28. AstellasPharmabv.Foreducationaluseonly. Preservation of endothelial function by NG cocktail1 Mean concentration-relaxation curves for Ach in precontracted arteries: • unchanged Ach-induced relaxation • preserved endothelial function Guo-Wei He et al. J Thorac Cardiovasc Surg 2008;136:673-80. 1. Nicardipine (30 µmol/L) + Nitroglycerin (30 µmol/L). A: Internal thoracic artery; B: Radial artery; ACh: acetylcholine.
  • 29. AstellasPharmabv.Foreducationaluseonly. General conclusion • Vasospasm remains an important concern in coronary artery bypass grafting • Perioperative and postoperative premature constriction of graft conduits may be reversed or prevented by antispasm protocols. • No single vasodilator is expected to be effective to reverse or prevent all mechanisms. • Arterial conduits that are more vulnerable to the most intense vasospasm are also the most efficaciously treated. • Nicardipine + nitroglycerin cocktail achieved rapid onset effective relaxation and prophylactic antispastic effect at therapeutic concentration Chanda et al. Ann Thorac Surg 2001;72:476-80. He GW. Ann Cardiothorac Surg 2013;2(4):507-518.